MNPR

38.78

10.56% -4.58

Dopo l'orario di chiusura: 40.71 1.93 +4.98%

Monopar Therapeutics Inc (MNPR)

Panoramica Notizia Cronologia dei prezzi Financials Forum Previsione

Precedente Chiudi:

$43.36

Aprire:

$40.25

Volume 24 ore:

18,578

Relative Volume:

0.52

Capitalizzazione di mercato:

$256.59M

Reddito:

Utile/perdita netta:

$-7.12M

Rapporto P/E:

-16.86

EPS:

-2.3

Flusso di cassa netto:

$-6.82M

1 W Prestazione:

-7.58%

1M Prestazione:

+29.27%

6M Prestazione:

+145.75%

1 anno Prestazione:

+4,796%

Intervallo 1D:

$38.78

$43.59

Intervallo di 1 settimana:

$38.78

$46.60

Portata 52W:

$0.3438

$54.30

Monopar Therapeutics Inc Stock (MNPR) Company Profile

Nome

Monopar Therapeutics Inc

Settore

Healthcare (1158)

Industria

Biotechnology (664)

Telefono

(847) 388-0349

Indirizzo

1000 SKOKIE BLVD SUITE 350, WILMETTE

Dipendente

Cinguettio

Prossima data di guadagno

2024-11-07

Ultimi documenti SEC

MNPR's Discussions on Twitter

Confronta MNPR con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
MNPR Monopar Therapeutics Inc	38.78	256.59M	0	-7.12M	-6.82M	-2.30
VRTX Vertex Pharmaceuticals Inc	450.03	129.44B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	558.52	61.42B	14.09B	4.50B	2.96B	39.28
ARGX Argen X Se Adr	615.11	38.44B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	269.81	33.29B	2.35B	-269.70M	-75.39M	-2.09
ONC Beigene Ltd Adr	241.75	26.95B	3.81B	-644.79M	-669.77M	-6.24

Monopar Therapeutics Inc Stock (MNPR) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-03-19	Ripresa	Piper Sandler	Overweight
2025-01-10	Iniziato	Piper Sandler	Overweight
2024-10-11	Iniziato	Rodman & Renshaw	Buy
2021-01-28	Iniziato	ROTH Capital	Buy

Monopar Therapeutics Inc Borsa (MNPR) Ultime notizie

May 02, 2025

Geode Capital Management LLC Acquires 24,530 Shares of Monopar Therapeutics Inc. (NASDAQ:MNPR) - Defense World

May 02, 2025

Apr 30, 2025

Why Monopar Therapeutics Inc. (MNPR) is Surging in 2025 - Yahoo

Apr 30, 2025

Apr 29, 2025

Monopar Announces ALXN1840 Data Selected for Late-Breaker Presentation at EASL Congress 2025 - The Manila Times

Apr 29, 2025

Monopar Therapeutics Inc. acquired worldwide license to ALXN-18 from Alexion Pharmaceuticals, Inc. for approximately $110 million. - marketscreener.com

Apr 10, 2025

Apr 06, 2025

(MNPR) Long Term Investment Analysis - news.stocktradersdaily.com

Apr 06, 2025

Apr 04, 2025

Major Shareholder Sells Big Chunk of Monopar Therapeutics Stock! - TipRanks

Apr 04, 2025

Monopar Therapeutics CEO Robinson sells $1.17 million in stock By Investing.com - Investing.com Canada

Apr 04, 2025

HC Wainwright Issues Negative Forecast for MNPR Earnings - Defense World

Apr 04, 2025

Jones Trading Reiterates “Hold” Rating for Monopar Therapeutics (NASDAQ:MNPR) - Defense World

Apr 04, 2025

Apr 03, 2025

What is HC Wainwright’s Forecast for MNPR FY2029 Earnings? - Defense World

Apr 03, 2025

Apr 02, 2025

Monopar Therapeutics downgraded to Hold from Buy at JonesResearch - TipRanks

Apr 02, 2025

We Think Monopar Therapeutics (NASDAQ:MNPR) Can Easily Afford To Drive Business Growth - Yahoo

Apr 02, 2025

Monopar Therapeutics (NASDAQ:MNPR) Receives “Buy” Rating from HC Wainwright - Defense World

Apr 02, 2025

Apr 01, 2025

Top 5 Small-cap Biotech Stocks of 2025 - Nasdaq

Apr 01, 2025

Monopar Therapeutics Stock Hits 52-Week High at $38.91 - MSN

Apr 01, 2025

Monopar Therapeutics Inc: Strategic Advancements and Promising Financial Projections Justify Buy Rating - TipRanks

Apr 01, 2025

Buy Rating for Monopar Therapeutics Inc: Strategic Advancements and Promising Financial Outlook - TipRanks

Apr 01, 2025

Mar 31, 2025

Monopar Therapeutics reports Q4 EPS ($2.23) vs. (60c) last year - TipRanks

Mar 31, 2025

Monopar Therapeutics sees cash runway through December 31, 2026 - TipRanks

Mar 31, 2025